CA1112171A - Substances carminatives contenant des huiles essentielles ou leur principe actif - Google Patents

Substances carminatives contenant des huiles essentielles ou leur principe actif

Info

Publication number: CA1112171A
Authority: CA; Canada
Prior art keywords: peppermint oil; carminative; oil; capsule; essential oils
Prior art date: 1979-03-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA323,439A

Other languages

English (en)

Inventor

John Rhodes

Brian K. Evans

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

JB Tillott Ltd

Original Assignee

JB Tillott Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-03-14

Filing date

1979-03-14

Publication date

1981-11-10

1979-03-14 Application filed by JB Tillott Ltd filed Critical JB Tillott Ltd

1979-03-14 Priority to CA323,439A priority Critical patent/CA1112171A/fr

1981-11-10 Application granted granted Critical

1981-11-10 Publication of CA1112171A publication Critical patent/CA1112171A/fr

Status Expired legal-status Critical Current

Links

230000002026 carminative effect Effects 0.000 title abstract description 10
239000000341 volatile oil Substances 0.000 title description 5
238000002360 preparation method Methods 0.000 title description 3
239000001525 mentha piperita l. herb oil Substances 0.000 claims abstract description 23
235000019477 peppermint oil Nutrition 0.000 claims abstract description 23
239000002775 capsule Substances 0.000 claims abstract description 21
238000000576 coating method Methods 0.000 claims description 8
239000011248 coating agent Substances 0.000 claims description 6
229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 3
229940081734 cellulose acetate phthalate Drugs 0.000 claims description 3
239000007903 gelatin capsule Substances 0.000 claims description 3
208000002551 irritable bowel syndrome Diseases 0.000 abstract description 10
210000000936 intestine Anatomy 0.000 abstract description 4
239000001828 Gelatine Substances 0.000 abstract description 3
229920000159 gelatin Polymers 0.000 abstract description 3
235000019322 gelatine Nutrition 0.000 abstract description 3
208000028774 intestinal disease Diseases 0.000 abstract description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
210000002784 stomach Anatomy 0.000 description 5
230000009471 action Effects 0.000 description 4
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 4
239000002702 enteric coating Substances 0.000 description 4
238000009505 enteric coating Methods 0.000 description 4
238000000034 method Methods 0.000 description 4
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
241001479543 Mentha x piperita Species 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
235000012054 meals Nutrition 0.000 description 3
210000004400 mucous membrane Anatomy 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
230000008569 process Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
XHXUANMFYXWVNG-ADEWGFFLSA-N (-)-Menthyl acetate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(C)=O XHXUANMFYXWVNG-ADEWGFFLSA-N 0.000 description 2
208000004998 Abdominal Pain Diseases 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
208000012258 Diverticular disease Diseases 0.000 description 2
206010013554 Diverticulum Diseases 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
241000207923 Lamiaceae Species 0.000 description 2
235000016257 Mentha pulegium Nutrition 0.000 description 2
235000004357 Mentha x piperita Nutrition 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
210000001198 duodenum Anatomy 0.000 description 2
235000001050 hortel pimenta Nutrition 0.000 description 2
229940041616 menthol Drugs 0.000 description 2
239000000203 mixture Substances 0.000 description 2
239000010491 poppyseed oil Substances 0.000 description 2
210000000813 small intestine Anatomy 0.000 description 2
NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
239000001605 (5-methyl-2-propan-2-ylcyclohexyl) acetate Substances 0.000 description 1
VYVKHNNGDFVQGA-UHFFFAOYSA-N 3,4-dimethoxybenzoic acid 4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butyl ester Chemical compound C=1C=C(OC)C=CC=1CC(C)N(CC)CCCCOC(=O)C1=CC=C(OC)C(OC)=C1 VYVKHNNGDFVQGA-UHFFFAOYSA-N 0.000 description 1
208000002310 Achlorhydria Diseases 0.000 description 1
206010008399 Change of bowel habit Diseases 0.000 description 1
208000002881 Colic Diseases 0.000 description 1
XHXUANMFYXWVNG-UHFFFAOYSA-N D-menthyl acetate Natural products CC(C)C1CCC(C)CC1OC(C)=O XHXUANMFYXWVNG-UHFFFAOYSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
206010015137 Eructation Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
230000002921 anti-spasmodic effect Effects 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000008199 coating composition Substances 0.000 description 1
208000027742 colicky pain Diseases 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
CURUTKGFNZGFSE-UHFFFAOYSA-N dicyclomine Chemical compound C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 description 1
229960002777 dicycloverine Drugs 0.000 description 1
HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
229960004192 diphenoxylate Drugs 0.000 description 1
238000004821 distillation Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000002662 enteric coated tablet Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000003172 expectorant agent Substances 0.000 description 1
230000003419 expectorant effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
230000036541 health Effects 0.000 description 1
208000024798 heartburn Diseases 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
239000002085 irritant Substances 0.000 description 1
210000001630 jejunum Anatomy 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
239000008141 laxative Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229960003577 mebeverine Drugs 0.000 description 1
229930007503 menthone Natural products 0.000 description 1
150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
231100000067 mild irritant Toxicity 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
-1 papverine Chemical compound 0.000 description 1
230000007170 pathology Effects 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
230000001543 purgative effect Effects 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1

Landscapes

Medicinal Preparation (AREA)

CA323,439A 1979-03-14 1979-03-14 Substances carminatives contenant des huiles essentielles ou leur principe actif Expired CA1112171A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA323,439A CA1112171A (fr)	1979-03-14	1979-03-14	Substances carminatives contenant des huiles essentielles ou leur principe actif

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA323,439A CA1112171A (fr)	1979-03-14	1979-03-14	Substances carminatives contenant des huiles essentielles ou leur principe actif

Publications (1)

Publication Number	Publication Date
CA1112171A true CA1112171A (fr)	1981-11-10

Family

ID=4113748

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA323,439A Expired CA1112171A (fr)	1979-03-14	1979-03-14	Substances carminatives contenant des huiles essentielles ou leur principe actif

Country Status (1)

Country	Link
CA (1)	CA1112171A (fr)

1979
- 1979-03-14 CA CA323,439A patent/CA1112171A/fr not_active Expired

Legal Events

Date	Code	Title	Description
1998-11-10	MKEX	Expiry

Publication	Publication Date	Title
EP0015334B1 (fr)	1982-05-19	Préparations carminatives contenant l'huile de menthe ou ses composés actifs
US5464632A (en)	1995-11-07	Rapidly disintegratable multiparticular tablet
CA2092074C (fr)	1998-05-19	Tablette multiparticulee a desintegration rapide
CA2269078C (fr)	2012-01-24	Formulations enterales de compositions polymeres pro-anthocyanidiques a proprietes anti-diarrheiques
US4555399A (en)	1985-11-26	Aspirin tablet
US5023245A (en)	1991-06-11	Improved niacin formulation
CA2221356C (fr)	2003-12-30	Traitement d'affections intestinales inflammatoires a l'aide de formes galeniques orales d'acides omega-3 polyinsatures
CA1172570A (fr)	1984-08-14	Composes pharmaceutiques administres par voie orale
US4900558A (en)	1990-02-13	Sustained release ibuprofen formulation including a core of ibuprofen and a microcrystalline cellulose and a covering of acrylic polymer and hydroxylated cellulose derivative
EP0804172B1 (fr)	2002-01-09	Forme posologique au potassium a liberation controlee
JPH07330628A (ja)	1995-12-19	薬剤組成物及びこれを用いた治療法
US5589190A (en)	1996-12-31	Sustained-release compositions of alfuzosin hydrochloride
JPS62501845A (ja)	1987-07-23	制御放出塩化カリウム
JP3018160B2 (ja)	2000-03-13	月経困難症及び／又は月経前症候群の軽減用薬剤
JPS61183220A (ja)	1986-08-15	鎮痛性を有する医薬組成物
CA2022422A1 (fr)	1991-02-03	Methode et preparation pour diminuer les risques d'infarctus du myocarde
US4608258A (en)	1986-08-26	Medicament for treatment of diarrhea
CA1112171A (fr)	1981-11-10	Substances carminatives contenant des huiles essentielles ou leur principe actif
EP0261693A1 (fr)	1988-03-30	Régulateur de lipides traité
US5602180A (en)	1997-02-11	Method of administering EDTA complexes
US6165482A (en)	2000-12-26	Gastrointestinal drug composition
RU2199336C1 (ru)	2003-02-27	Биологически активное вещество
JPH0368012B2 (fr)	1991-10-25
US20140116916A1 (en)	2014-05-01	Therapy for Constipation
CN1138826A (zh)	1996-12-25	5-硝基咪唑衍生物微粒